the heart, leading to the two major subcategories of cerebrovascular and cardiovascular diseases (CVDs). Both cerebral and cardiovascular diseases (CCVDs) are prevalent, leading to high percentages of mortality and morbidity worldwide. [3,4] Over the years, several medical approaches have been used to treat these diseases. For example, mechanical thrombectomy and tissue plasminogen activator (tPA) administration are the standard therapies for treating ischemic stroke that can undoubtedly help numerous patients. However, limitations like the short time window for applying these therapies (≈3-6 h) and the transformation of ischemic stroke to hemorrhagic due to tPA administration constrains their use to most patients. Following the same rationale, the standard treatment for myocardial ischemia that leads to infarction uses thrombolytics like aspirin and tissue or urokinase plasminogen activator (uPA), in combination with antihypertensives to reduce blood pressure and nitroglycerine to widen the blood vessels. Nevertheless, similar side effects as in ischemic stroke inhibit their unconditioned use. Notably, most of the current commercial treatments are focused on the imminent effects of CCVDs without considering the post-ischemia side effects. In particular, blood flow restoration followed by damage mitigation in the brain or the heart is the primary goal of the current CCVDs' treatment. Although these treatments increase the patients' survival, and to a limited extent, attenuate the disease's symptoms, they are unable to properly cure the disease due to the detrimental side effects caused by vascular ischemia.Several "smart" strategies have been suggested to eliminate the restraints of the current medical treatments and improve their therapeutic outcome. [5,6] These strategies involve using biomaterials that can read the biochemical alterations in the diseased microenvironment and respond in predetermined ways. [7,8] These "smart" biomaterials or stimuli-responsive materials can alter their physicochemical properties or structure depending on various stimuli. Additionally, they can exert a therapeutic effect either by the release of an encapsulated therapeutic (e.g., tPA/uPA) [9,10] or because of an inherent property (e.g., antioxidant CeO 2 nanoparticles (NPs)). [11][12][13] It should be noted that the stimuli can be internal, like acidic pH, platelet activation, reactive oxygen species (ROS) concentration, and enzyme concentration, or external, like magnetic and electric fields, ultrasound, and light. The reason why these stimuliresponsive biomaterials are at the forefront of research lies in the complex pathophysiology of the CCVDs that renders simple Cardiovascular and cerebrovascular diseases (CCVDs) describe abnormal vascular system conditions affecting the brain and heart. Among these, ischemic heart disease and ischemic stroke are the leading causes of death worldwide, resulting in 16% and 11% of deaths globally. Although several therapeutic approaches are presented over the years, the continuously increasin...